Drug Profile
Apremilast - 3SBio
Alternative Names: AP 506Latest Information Update: 23 Dec 2021
Price :
$50
*
At a glance
- Originator 3SBio
- Class Acetamides; Anti-inflammatories; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Isoindoles; Phthalimides; Skin disorder therapies; Small molecules; Sulfones
- Mechanism of Action Interleukin 23 inhibitors; Tumour necrosis factor alpha inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Psoriatic arthritis
Most Recent Events
- 22 Apr 2020 3SBio pipeline, April 2020 - Antirheumatics DC addition req sent; intro updated; NDR processed; ADS added
- 22 Apr 2020 Phase-I development is ongoing in China (3SBio pipeline, April 2020)
- 28 Oct 2019 No recent reports of development identified for phase-I development in Psoriatic-arthritis in China